Going beyond disease management
AccurEdit Therapeutics is committed to developing cures for severe and life-threatening diseases through in vivo gene editing. The company has established an industry-leading end-to-end technology platform focused on RNA synthesis, editing, and delivery technologies. In October 2023, AccurEdit became the first company in China to demonstrate safe and effective systemic CRISPR gene editing in humans. Its lead program ART001 is an LNP-delivered in vivo gene editing therapy and received FDA RMAT designation. AccurEdit follows a patient-oriented philosophy pursuing single-dose curative therapy via a highly efficient technology platform.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2023
Create a free account to see which investors have funded this company.
Create Free AccountClinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.
Biopharmaceutical company developing multispecific antibody therapies for retinal and complex dis...
UK biotech developing cell conversion technology for life-saving cell therapies.
